FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980339341> ?p ?o ?g. }

• W2980339341 endingPage "24" @default.
• W2980339341 startingPage "21" @default.
• W2980339341 abstract "Purpose: To compare the efficacy, safety, and potential advantages of the preservative-free versus preserved brimonidine %0.15 preparations in patients with primer open-angle glaucoma (POAG) or ocular hypertension (OHT).Methods: Forty-two eyes of the 21 treatment-naive patients with POAG or OHT were enrolled in this study. Eyes were randomly assigned to receive brimonidine-purite 0.15% or preservative-free brimonidine 0.15% two times daily. Efficacy of the two eye drops was assessed by measuring the intraocular pressure (IOP) at 9-10 am at baseline and week 4. Safety and potential advantages of the drops were evaluated at weeks 4 in terms of ocular symptoms and tear parameters. Ocular symptom values of the patients were evaluated with a scale of 0-4 (0 = no discomfort and 4 = severe discomfort).Results: Both of the brimonidine tartrate formulations resulted in statistically similar IOP reduction (preserved formulation; -5.2 mmHg [22.9% reduction] preservative-free formulation; -5.7 mmHg [24.1% reduction], p = 0.37). It was found that brimonidine tartrate formulations with and without topical preservatives did not produce a statistically significant difference in pain, stinging, and blurred vision at the upon instillation (p > 0.05). However, the burning sensation was significantly higher in the preservative-free formulation at the first instillation compared to the preserved formulation (p = 0.01). Also, there was no statistically significant difference between the two formulations in terms of symptoms (itching, burning, tearing, stinging, and photophobia) and tear parameters during the day (p > 0.05).Conclusions: Although topical preservative-free brimonidine tartrate treated eyes had a more burning sensation at the first drop, the two formulations were similar in terms of ocular tolerability in the short term period. Also, both formulations were found to reduce IOP at a similar rate." @default.
• W2980339341 created "2019-10-25" @default.
• W2980339341 creator A5021335867 @default.
• W2980339341 creator A5074131531 @default.
• W2980339341 date "2019-10-27" @default.
• W2980339341 modified "2023-10-02" @default.
• W2980339341 title "Preservative-free <i>versus</i> preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages" @default.
• W2980339341 cites W1972090852 @default.
• W2980339341 cites W1974991464 @default.
• W2980339341 cites W1978986531 @default.
• W2980339341 cites W1980379617 @default.
• W2980339341 cites W2001206574 @default.
• W2980339341 cites W2003892344 @default.
• W2980339341 cites W2006804172 @default.
• W2980339341 cites W2009259670 @default.
• W2980339341 cites W2032065302 @default.
• W2980339341 cites W2035689780 @default.
• W2980339341 cites W2036341177 @default.
• W2980339341 cites W2057266151 @default.
• W2980339341 cites W2059897265 @default.
• W2980339341 cites W2068119665 @default.
• W2980339341 cites W2108069709 @default.
• W2980339341 cites W2136379937 @default.
• W2980339341 cites W2143743549 @default.
• W2980339341 cites W2148890166 @default.
• W2980339341 cites W2160605010 @default.
• W2980339341 cites W2169883707 @default.
• W2980339341 cites W2839861907 @default.
• W2980339341 cites W2896544369 @default.
• W2980339341 doi "https://doi.org/10.1080/15569527.2019.1680685" @default.
• W2980339341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31615279" @default.
• W2980339341 hasPublicationYear "2019" @default.
• W2980339341 type Work @default.
• W2980339341 sameAs 2980339341 @default.
• W2980339341 citedByCount "13" @default.
• W2980339341 countsByYear W29803393412021 @default.
• W2980339341 countsByYear W29803393412022 @default.
• W2980339341 countsByYear W29803393412023 @default.
• W2980339341 crossrefType "journal-article" @default.
• W2980339341 hasAuthorship W2980339341A5021335867 @default.
• W2980339341 hasAuthorship W2980339341A5074131531 @default.
• W2980339341 hasConcept C118487528 @default.
• W2980339341 hasConcept C2776521421 @default.
• W2980339341 hasConcept C2777625524 @default.
• W2980339341 hasConcept C2778190193 @default.
• W2980339341 hasConcept C2778527774 @default.
• W2980339341 hasConcept C2780590625 @default.
• W2980339341 hasConcept C2781092963 @default.
• W2980339341 hasConcept C71924100 @default.
• W2980339341 hasConceptScore W2980339341C118487528 @default.
• W2980339341 hasConceptScore W2980339341C2776521421 @default.
• W2980339341 hasConceptScore W2980339341C2777625524 @default.
• W2980339341 hasConceptScore W2980339341C2778190193 @default.
• W2980339341 hasConceptScore W2980339341C2778527774 @default.
• W2980339341 hasConceptScore W2980339341C2780590625 @default.
• W2980339341 hasConceptScore W2980339341C2781092963 @default.
• W2980339341 hasConceptScore W2980339341C71924100 @default.
• W2980339341 hasIssue "1" @default.
• W2980339341 hasLocation W29803393411 @default.
• W2980339341 hasLocation W29803393412 @default.
• W2980339341 hasOpenAccess W2980339341 @default.
• W2980339341 hasPrimaryLocation W29803393411 @default.
• W2980339341 hasRelatedWork W1975088893 @default.
• W2980339341 hasRelatedWork W2015478147 @default.
• W2980339341 hasRelatedWork W2136578682 @default.
• W2980339341 hasRelatedWork W2275917273 @default.
• W2980339341 hasRelatedWork W2377183459 @default.
• W2980339341 hasRelatedWork W2612340917 @default.
• W2980339341 hasRelatedWork W2998956409 @default.
• W2980339341 hasRelatedWork W3016200193 @default.
• W2980339341 hasRelatedWork W4313544731 @default.
• W2980339341 hasRelatedWork W2164562580 @default.
• W2980339341 hasVolume "39" @default.
• W2980339341 isParatext "false" @default.
• W2980339341 isRetracted "false" @default.
• W2980339341 magId "2980339341" @default.
• W2980339341 workType "article" @default.